{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,12,4]],"date-time":"2025-12-04T09:48:10Z","timestamp":1764841690579},"reference-count":67,"publisher":"Elsevier BV","issue":"3","license":[{"start":{"date-parts":[[2012,6,1]],"date-time":"2012-06-01T00:00:00Z","timestamp":1338508800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Pharmacology & Therapeutics"],"published-print":{"date-parts":[[2012,6]]},"DOI":"10.1016\/j.pharmthera.2012.02.006","type":"journal-article","created":{"date-parts":[[2012,3,17]],"date-time":"2012-03-17T05:31:34Z","timestamp":1331962294000},"page":"345-354","source":"Crossref","is-referenced-by-count":4,"title":["Novel antithrombotic agents for atrial fibrillation"],"prefix":"10.1016","volume":"134","author":[{"given":"Maria M.","family":"Niespialowska-Steuden","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Vias","family":"Markides","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Diana A.","family":"Gorog","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.pharmthera.2012.02.006_bb0340","doi-asserted-by":"crossref","first-page":"633","DOI":"10.1016\/S0140-6736(96)03487-3","article-title":"Adjusted-dose warfarin versus low-intensity, fixed-dose warfarin plus aspirin for high-risk patients with atrial fibrillation: stroke prevention in atrial fibrillation III randomised clinical trial","volume":"348","year":"1996","journal-title":"Lancet"},{"key":"10.1016\/j.pharmthera.2012.02.006_bb0010","doi-asserted-by":"crossref","first-page":"699","DOI":"10.1056\/NEJMoa1105819","article-title":"Apixaban with antiplatelet therapy after acute coronary syndrome","volume":"365","author":"Alexander","year":"2011","journal-title":"N Engl J Med"},{"key":"10.1016\/j.pharmthera.2012.02.006_bb0015","doi-asserted-by":"crossref","first-page":"165","DOI":"10.1161\/CIRCULATIONAHA.111.031153","article-title":"New oral anticoagulants should not be used as first-line agents to prevent thromboembolism in patients with atrial fibrillation","volume":"125","author":"Ansell","year":"2012","journal-title":"Circulation"},{"key":"10.1016\/j.pharmthera.2012.02.006_bb0020","doi-asserted-by":"crossref","first-page":"244","DOI":"10.18553\/jmcp.2009.15.3.244","article-title":"Meta-analysis to assess the quality of warfarin control in atrial fibrillation patients in the United States","volume":"15","author":"Baker","year":"2009","journal-title":"J Manag Care Pharm"},{"key":"10.1016\/j.pharmthera.2012.02.006_bb0025","doi-asserted-by":"crossref","first-page":"1263","DOI":"10.1160\/TH10-05-0328","article-title":"Clinical laboratory measurement of direct factor Xa inhibitors: anti-Xa assay is preferable to prothrombin time assay","volume":"104","author":"Barrett","year":"2010","journal-title":"Thromb Haemost"},{"key":"10.1016\/j.pharmthera.2012.02.006_bb0030","doi-asserted-by":"crossref","first-page":"2499","DOI":"10.1056\/NEJMoa1007903","article-title":"Oral rivaroxaban for symptomatic venous thromboembolism","volume":"363","author":"Bauersachs","year":"2010","journal-title":"N Engl J Med"},{"key":"10.1016\/j.pharmthera.2012.02.006_bb0035","series-title":"Advisory committee briefing document","author":"Boehringer Ingelheim Pharmaceuticals","year":"2010"},{"key":"10.1016\/j.pharmthera.2012.02.006_bb0040","doi-asserted-by":"crossref","first-page":"1503","DOI":"10.2165\/11595540-000000000-00000","article-title":"Edoxaban: a new oral direct factor Xa inhibitor","volume":"71","author":"Camm","year":"2011","journal-title":"Drugs"},{"key":"10.1016\/j.pharmthera.2012.02.006_bb0045","doi-asserted-by":"crossref","first-page":"1360","DOI":"10.1093\/europace\/euq350","article-title":"Guidelines for the management of atrial fibrillation: the task force for the management of atrial fibrillation of the European Society of Cardiology (ESC)","volume":"12","author":"Camm","year":"2010","journal-title":"Europace"},{"key":"10.1016\/j.pharmthera.2012.02.006_bb0050","doi-asserted-by":"crossref","first-page":"1192","DOI":"10.1592\/phco.31.12.1192","article-title":"Role of pharmacogenomics in the management of traditional and novel oral anticoagulants","volume":"31","author":"Cavallari","year":"2011","journal-title":"Pharmacotherapy"},{"key":"10.1016\/j.pharmthera.2012.02.006_bb0060","doi-asserted-by":"crossref","first-page":"806","DOI":"10.1056\/NEJMoa1007432","article-title":"Apixaban in patients with atrial fibrillation","volume":"364","author":"Connolly","year":"2011","journal-title":"N Engl J Med"},{"key":"10.1016\/j.pharmthera.2012.02.006_bb0065","doi-asserted-by":"crossref","first-page":"1139","DOI":"10.1056\/NEJMoa0905561","article-title":"Dabigatran versus warfarin in patients with atrial fibrillation","volume":"361","author":"Connolly","year":"2009","journal-title":"N Engl J Med"},{"key":"10.1016\/j.pharmthera.2012.02.006_bb0055","doi-asserted-by":"crossref","first-page":"1903","DOI":"10.1016\/S0140-6736(06)68845-4","article-title":"Clopidogrel plus aspirin versus oral anticoagulation for atrial fibrillation in the Atrial fibrillation Clopidogrel Trial with Irbesartan for prevention of Vascular Events (ACTIVE W): a randomised controlled trial","volume":"367","author":"Connolly","year":"2006","journal-title":"Lancet"},{"key":"10.1016\/j.pharmthera.2012.02.006_bb0070","article-title":"The atlas of heart disease and stroke","author":"Deaths from stroke","year":"2004"},{"issue":"4","key":"10.1016\/j.pharmthera.2012.02.006_bb8000","first-page":"391","article-title":"Treatment of excessive anticoagulation with phytonadione (vitamin K): A meta-analysis","volume":"166","author":"Dezee","year":"2006","journal-title":"Arch Intern Med"},{"key":"10.1016\/j.pharmthera.2012.02.006_bb0075","doi-asserted-by":"crossref","first-page":"1534","DOI":"10.1161\/01.STR.24.10.1534","article-title":"Transient platelet accumulation in the rat brain after common carotid artery thrombosis. An 111In-labeled platelet study","volume":"24","author":"Dietrich","year":"1993","journal-title":"Stroke"},{"key":"10.1016\/j.pharmthera.2012.02.006_bb0080","doi-asserted-by":"crossref","first-page":"1573","DOI":"10.1161\/CIRCULATIONAHA.111.029017","article-title":"Reversal of rivaroxaban and dabigatran by prothrombin complex concentrate: a randomized, placebo-controlled, crossover study in healthy subjects","volume":"124","author":"Eerenberg","year":"2011","journal-title":"Circulation"},{"key":"10.1016\/j.pharmthera.2012.02.006_bb0090","doi-asserted-by":"crossref","first-page":"2765","DOI":"10.1056\/NEJMoa0800374","article-title":"Rivaroxaban versus enoxaparin for thromboprophylaxis after hip arthroplasty","volume":"358","author":"Eriksson","year":"2008","journal-title":"N Engl J Med"},{"key":"10.1016\/j.pharmthera.2012.02.006_bb0095","doi-asserted-by":"crossref","first-page":"2864","DOI":"10.1001\/jama.285.22.2864","article-title":"Validation of clinical classification schemes for predicting stroke: results from the National Registry of Atrial Fibrillation","volume":"285","author":"Gage","year":"2001","journal-title":"JAMA"},{"key":"10.1016\/j.pharmthera.2012.02.006_bb0100","doi-asserted-by":"crossref","first-page":"927","DOI":"10.7326\/0003-4819-131-12-199912210-00004","article-title":"Warfarin use among ambulatory patients with nonvalvular atrial fibrillation: the anticoagulation and risk factors in atrial fibrillation (ATRIA) study","volume":"131","author":"Go","year":"1999","journal-title":"Ann Intern Med"},{"key":"10.1016\/j.pharmthera.2012.02.006_bb0105","doi-asserted-by":"crossref","first-page":"981","DOI":"10.1056\/NEJMoa1107039","article-title":"Apixaban versus warfarin in patients with atrial fibrillation","volume":"365","author":"Granger","year":"2011","journal-title":"N Engl J Med"},{"key":"10.1016\/j.pharmthera.2012.02.006_bb0110","doi-asserted-by":"crossref","first-page":"159","DOI":"10.1161\/CIRCULATIONAHA.111.031146","article-title":"Newer oral anticoagulants should be used as first-line agents to prevent thromboembolism in patients with atrial fibrillation and risk factors for stroke or thromboembolism","volume":"125","author":"Granger","year":"2012","journal-title":"Circulation"},{"issue":"Suppl. 1","key":"10.1016\/j.pharmthera.2012.02.006_bb0115","first-page":"A39","article-title":"Recombinant factor VIIa reverses the effects of a high dose of rivaroxaban in baboons","volume":"36","author":"Gruber","year":"2007","journal-title":"Pathophysiol Haemost Thromb"},{"key":"10.1016\/j.pharmthera.2012.02.006_bb0120","doi-asserted-by":"crossref","first-page":"119S","DOI":"10.1177\/0091270011415527","article-title":"Clinical pharmacology basis of deriving dosing recommendations for dabigatran in patients with severe renal impairment","volume":"52","author":"Hariharan","year":"2012","journal-title":"J Clin Pharmacol"},{"key":"10.1016\/j.pharmthera.2012.02.006_bb0125","doi-asserted-by":"crossref","first-page":"1223","DOI":"10.1161\/01.STR.30.6.1223","article-title":"Factors associated with ischemic stroke during aspirin therapy in atrial fibrillation: analysis of 2012 participants in the SPAF I-III clinical trials. The Stroke Prevention in Atrial Fibrillation (SPAF) investigators","volume":"30","author":"Hart","year":"1999","journal-title":"Stroke"},{"key":"10.1016\/j.pharmthera.2012.02.006_bb0130","doi-asserted-by":"crossref","first-page":"949","DOI":"10.1093\/eurheartj\/ehi825","article-title":"Prevalence, incidence and lifetime risk of atrial fibrillation: the Rotterdam study","volume":"27","author":"Heeringa","year":"2006","journal-title":"Eur Heart J"},{"key":"10.1016\/j.pharmthera.2012.02.006_bb0135","doi-asserted-by":"crossref","first-page":"2689","DOI":"10.1161\/CIRCULATIONAHA.106.653048","article-title":"Major hemorrhage and tolerability of warfarin in the first year of therapy among elderly patients with atrial fibrillation","volume":"115","author":"Hylek","year":"2007","journal-title":"Circulation"},{"key":"10.1016\/j.pharmthera.2012.02.006_bb0140","doi-asserted-by":"crossref","first-page":"2N","DOI":"10.1016\/S0002-9149(98)00583-9","article-title":"Prevalence, incidence, prognosis, and predisposing conditions for atrial fibrillation: population-based estimates","volume":"82","author":"Kannel","year":"1998","journal-title":"Am J Cardiol"},{"key":"10.1016\/j.pharmthera.2012.02.006_bb0145","doi-asserted-by":"crossref","first-page":"593","DOI":"10.1111\/j.1365-2125.2011.04060.x","article-title":"New anticoagulants: how to deal with treatment failure and bleeding complications","volume":"72","author":"Kazmi","year":"2011","journal-title":"Br J Clin Pharmacol"},{"key":"10.1016\/j.pharmthera.2012.02.006_bb0150","doi-asserted-by":"crossref","first-page":"e26367","DOI":"10.1371\/journal.pone.0026367","article-title":"Crystal structure of thrombin in complex with S-variegin: insights of a novel mechanism of inhibition and design of tunable thrombin inhibitors","volume":"6","author":"Koh","year":"2011","journal-title":"PLoS One"},{"key":"10.1016\/j.pharmthera.2012.02.006_bb0160","doi-asserted-by":"crossref","first-page":"2776","DOI":"10.1056\/NEJMoa076016","article-title":"Rivaroxaban versus enoxaparin for thromboprophylaxis after total knee arthroplasty","volume":"358","author":"Lassen","year":"2008","journal-title":"N Engl J Med"},{"key":"10.1016\/j.pharmthera.2012.02.006_bb0165","doi-asserted-by":"crossref","first-page":"1760","DOI":"10.1161\/01.STR.27.10.1760","article-title":"Stroke severity in atrial fibrillation. The Framingham Study","volume":"27","author":"Lin","year":"1996","journal-title":"Stroke"},{"key":"10.1016\/j.pharmthera.2012.02.006_bb0170","doi-asserted-by":"crossref","first-page":"673","DOI":"10.1097\/FTD.0b013e3181f2f264","article-title":"Assays for measuring rivaroxaban: their suitability and limitations","volume":"32","author":"Lindhoff-Last","year":"2010","journal-title":"Ther Drug Monit"},{"key":"10.1016\/j.pharmthera.2012.02.006_bb0175","doi-asserted-by":"crossref","first-page":"1311","DOI":"10.1093\/eurheartj\/ehq117","volume":"31","author":"Lip","year":"2010","journal-title":"Eur Heart J"},{"key":"10.1016\/j.pharmthera.2012.02.006_bb0180","doi-asserted-by":"crossref","first-page":"263","DOI":"10.1378\/chest.09-1584","article-title":"Refining clinical risk stratification for predicting stroke and thromboembolism in atrial fibrillation using a novel risk factor-based approach: the Euro heart survey on atrial fibrillation","volume":"137","author":"Lip","year":"2010","journal-title":"Chest"},{"key":"10.1016\/j.pharmthera.2012.02.006_bb0185","doi-asserted-by":"crossref","first-page":"1042","DOI":"10.1161\/01.CIR.0000140263.20897.42","article-title":"Lifetime risk for development of atrial fibrillation: the Framingham Heart Study","volume":"110","author":"Lloyd-Jones","year":"2004","journal-title":"Circulation"},{"key":"10.1016\/j.pharmthera.2012.02.006_bb0190","series-title":"The pharmacological basis of therapeutics","first-page":"1347","article-title":"Anticoagulant thrombolytic, and antiplatelet drugs","author":"Majerus","year":"1996"},{"key":"10.1016\/j.pharmthera.2012.02.006_bb0195","doi-asserted-by":"crossref","first-page":"493","DOI":"10.1016\/S0140-6736(07)61233-1","article-title":"Warfarin versus aspirin for stroke prevention in an elderly community population with atrial fibrillation (the Birmingham Atrial Fibrillation Treatment of the Aged Study, BAFTA): a randomised controlled trial","volume":"370","author":"Mant","year":"2007","journal-title":"Lancet"},{"key":"10.1016\/j.pharmthera.2012.02.006_bb0200","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1056\/NEJMoa1112277","article-title":"Rivaroxaban in patients with a recent acute coronary syndrome","volume":"366","author":"Mega","year":"2012","journal-title":"N Engl J Med"},{"key":"10.1016\/j.pharmthera.2012.02.006_bb0205","doi-asserted-by":"crossref","first-page":"1843","DOI":"10.1161\/CIRCULATIONAHA.110.000786","article-title":"Safety and tolerability of atopaxar in the treatment of patients with acute coronary syndromes: the lessons from antagonizing the cellular effects of Thrombin-Acute Coronary Syndromes Trial","volume":"123","author":"O'Donoghue","year":"2011","journal-title":"Circulation"},{"key":"10.1016\/j.pharmthera.2012.02.006_bb0210","doi-asserted-by":"crossref","first-page":"743","DOI":"10.1177\/0091270009351883","article-title":"Clinical safety, tolerability, pharmacokinetics, and pharmacodynamics of the novel factor Xa inhibitor edoxaban in healthy volunteers","volume":"50","author":"Ogata","year":"2010","journal-title":"J Clin Pharmacol"},{"key":"10.1016\/j.pharmthera.2012.02.006_bb0215","doi-asserted-by":"crossref","first-page":"2781","DOI":"10.1093\/eurheartj\/ehr113","article-title":"Dabigatran vs. placebo in patients with acute coronary syndromes on dual antiplatelet therapy: a randomized, double-blind, phase II trial","volume":"32","author":"Oldgren","year":"2011","journal-title":"Eur Heart J"},{"key":"10.1016\/j.pharmthera.2012.02.006_bb0220","series-title":"European Stroke Conference Barcelone, Spain","article-title":"Baseline characteristics of the ROCKET AF study: comparison with recent atrial fibrillation studies","author":"Patel","year":"2010"},{"key":"10.1016\/j.pharmthera.2012.02.006_bb0225","doi-asserted-by":"crossref","first-page":"883","DOI":"10.1056\/NEJMoa1009638","article-title":"Rivaroxaban versus warfarin in nonvalvular atrial fibrillation","volume":"365","author":"Patel","year":"2011","journal-title":"N Engl J Med"},{"issue":"Suppl. 1","key":"10.1016\/j.pharmthera.2012.02.006_bb0230","first-page":"A40","article-title":"FEIBA reverses the effects of a high dose of rivaroxaban in rats","volume":"36","author":"Perzborn","year":"2007","journal-title":"Pathophysiol Haemost Thromb"},{"key":"10.1016\/j.pharmthera.2012.02.006_bb0235","doi-asserted-by":"crossref","first-page":"26","DOI":"10.1186\/2191-0855-1-26","article-title":"Purification and characterization of novel fibrinolytic proteases as potential antithrombotic agents from earthworm Perionyx excavatus","volume":"1","author":"Phan","year":"2011","journal-title":"AMB Expr"},{"key":"10.1016\/j.pharmthera.2012.02.006_bb0240","doi-asserted-by":"crossref","first-page":"1093","DOI":"10.1378\/chest.10-0134","article-title":"A novel user-friendly score (HAS-BLED) to assess 1-year risk of major bleeding in patients with atrial fibrillation: the Euro Heart Survey","volume":"138","author":"Pisters","year":"2010","journal-title":"Chest"},{"key":"10.1016\/j.pharmthera.2012.02.006_bb0245","doi-asserted-by":"crossref","first-page":"e97","DOI":"10.1016\/j.thromres.2011.10.009","article-title":"Liporetro-D-peptides - A novel class of highly selective thrombin inhibitors","volume":"129","author":"Poyarkov","year":"2012","journal-title":"Thromb Res"},{"key":"10.1016\/j.pharmthera.2012.02.006_bb0250","doi-asserted-by":"crossref","first-page":"e18","DOI":"10.1161\/CIR.0b013e3182009701","article-title":"Heart disease and stroke statistics\u20142011 update: a report from the American Heart Association","volume":"123","author":"Roger","year":"2011","journal-title":"Circulation"},{"key":"10.1016\/j.pharmthera.2012.02.006_bb0255","doi-asserted-by":"crossref","first-page":"736","DOI":"10.1161\/01.STR.30.4.736","article-title":"Stroke incidence and survival among middle-aged adults: 9-year follow-up of the Atherosclerosis Risk in Communities (ARIC) cohort","volume":"30","author":"Rosamond","year":"1999","journal-title":"Stroke"},{"key":"10.1016\/j.pharmthera.2012.02.006_bb0155","series-title":"Medscape","article-title":"Atrial fibrillation","author":"Rosenthal","year":"2011"},{"key":"10.1016\/j.pharmthera.2012.02.006_bb0260","doi-asserted-by":"crossref","first-page":"635","DOI":"10.1016\/j.ahj.2010.06.042","volume":"160","author":"Ruff","year":"2010","journal-title":"Am Heart J"},{"key":"10.1016\/j.pharmthera.2012.02.006_bb0265","doi-asserted-by":"crossref","first-page":"815","DOI":"10.1160\/TH09-03-0176","article-title":"Assessment of laboratory assays to measure rivaroxaban\u2014an oral, direct factor Xa inhibitor","volume":"103","author":"Samama","year":"2010","journal-title":"Thromb Haemost"},{"key":"10.1016\/j.pharmthera.2012.02.006_bb0270","doi-asserted-by":"crossref","first-page":"2342","DOI":"10.1056\/NEJMoa0906598","article-title":"Dabigatran versus warfarin in the treatment of acute venous thromboembolism","volume":"361","author":"Schulman","year":"2009","journal-title":"N Engl J Med"},{"key":"10.1016\/j.pharmthera.2012.02.006_bb0275","doi-asserted-by":"crossref","first-page":"1255","DOI":"10.1016\/0140-6736(93)92358-Z","article-title":"Secondary prevention in non-rheumatic atrial fibrillation after transient ischaemic attack or minor stroke. EAFT (European Atrial Fibrillation Trial) Study Group","volume":"342","year":"1993","journal-title":"Lancet"},{"key":"10.1016\/j.pharmthera.2012.02.006_bb0280","doi-asserted-by":"crossref","first-page":"292","DOI":"10.1111\/j.1365-2125.2007.02899.x","article-title":"The pharmacokinetics, pharmacodynamics and tolerability of dabigatran etexilate, a new oral direct thrombin inhibitor, in healthy male subjects","volume":"64","author":"Stangier","year":"2007","journal-title":"Br J Clin Pharmacol"},{"key":"10.1016\/j.pharmthera.2012.02.006_bb0285","doi-asserted-by":"crossref","first-page":"40","DOI":"10.1002\/clc.4960270111","article-title":"Mortality and rate of stroke or embolism in atrial fibrillation during long-term follow-up in the embolism in left atrial thrombi (ELAT) study","volume":"27","author":"Stollberger","year":"2004","journal-title":"Clin Cardiol"},{"key":"10.1016\/j.pharmthera.2012.02.006_bb0290","doi-asserted-by":"crossref","first-page":"397","DOI":"10.1517\/14740338.6.4.397","article-title":"The direct thrombin inhibitor ximelagatran\/melagatran: a systematic review on clinical applications and an evidence based assessment of risk benefit profile","volume":"6","author":"Testa","year":"2007","journal-title":"Expert Opin Drug Saf"},{"key":"10.1016\/j.pharmthera.2012.02.006_bb0085","doi-asserted-by":"crossref","first-page":"1505","DOI":"10.1056\/NEJM199011293232201","article-title":"The effect of low-dose warfarin on the risk of stroke in patients with nonrheumatic atrial fibrillation. The Boston area anticoagulation trial for atrial fibrillation investigators","volume":"323","year":"1990","journal-title":"N Engl J Med"},{"key":"10.1016\/j.pharmthera.2012.02.006_bb0295","doi-asserted-by":"crossref","first-page":"20","DOI":"10.1056\/NEJMoa1109719","article-title":"Thrombin-receptor antagonist vorapaxar in Acute Coronary Syndromes","volume":"366","author":"Tricoci","year":"2012","journal-title":"N Eng J Med"},{"key":"10.1016\/j.pharmthera.2012.02.006_bb0305","doi-asserted-by":"crossref","first-page":"175","DOI":"10.2174\/157340310791658721","article-title":"Cardiac workup of ischemic stroke","volume":"6","author":"Ustrell","year":"2010","journal-title":"Curr Cardiol Rev"},{"key":"10.1016\/j.pharmthera.2012.02.006_bb0310","doi-asserted-by":"crossref","first-page":"1116","DOI":"10.1160\/TH09-11-0758","article-title":"Dabigatran etexilate\u2014a novel, reversible, oral direct thrombin inhibitor: interpretation of coagulation assays and reversal of anticoagulant activity","volume":"103","author":"van Ryn","year":"2010","journal-title":"Thromb Haemost"},{"key":"10.1016\/j.pharmthera.2012.02.006_bb0315","doi-asserted-by":"crossref","first-page":"413","DOI":"10.2165\/11533530-000000000-00000","volume":"10","author":"Vorapaxar","year":"2010","journal-title":"Am J Cardiovasc Drugs"},{"key":"10.1016\/j.pharmthera.2012.02.006_bb0320","doi-asserted-by":"crossref","first-page":"975","DOI":"10.1016\/S0140-6736(10)61194-4","article-title":"Efficacy and safety of dabigatran compared with warfarin at different levels of international normalised ratio control for stroke prevention in atrial fibrillation: an analysis of the RE-LY trial","volume":"376","author":"Wallentin","year":"2010","journal-title":"Lancet"},{"key":"10.1016\/j.pharmthera.2012.02.006_bb0325","doi-asserted-by":"crossref","first-page":"1056","DOI":"10.1124\/dmd.108.025569","article-title":"Metabolism and excretion of rivaroxaban, an oral, direct factor Xa inhibitor, in rats, dogs, and humans","volume":"37","author":"Weinz","year":"2009","journal-title":"Drug Metab Dispos"},{"key":"10.1016\/j.pharmthera.2012.02.006_bb0330","doi-asserted-by":"crossref","first-page":"983","DOI":"10.1161\/01.STR.22.8.983","article-title":"Atrial fibrillation as an independent risk factor for stroke: the Framingham Study","volume":"22","author":"Wolf","year":"1991","journal-title":"Stroke"},{"key":"10.1016\/j.pharmthera.2012.02.006_bb0335","doi-asserted-by":"crossref","first-page":"1637","DOI":"10.1111\/j.1538-7836.2004.00899.x","article-title":"Atrial fibrillation and thrombosis: immunohistochemical differences between in situ and embolized thrombi","volume":"2","author":"Wysokinski","year":"2004","journal-title":"J Thromb Haemost"}],"container-title":["Pharmacology & Therapeutics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S016372581200054X?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S016372581200054X?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2022,1,4]],"date-time":"2022-01-04T10:54:49Z","timestamp":1641293689000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S016372581200054X"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2012,6]]},"references-count":67,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2012,6]]}},"alternative-id":["S016372581200054X"],"URL":"https:\/\/doi.org\/10.1016\/j.pharmthera.2012.02.006","relation":{},"ISSN":["0163-7258"],"issn-type":[{"value":"0163-7258","type":"print"}],"subject":[],"published":{"date-parts":[[2012,6]]}}}